HANSHOW
September 2022, Hanshow, a professional digital store solution provider (SP), has officially released a whitepaper called “Hanshow Works with Intel and Microsoft to Accelerate Smart Retail Innovation”，written jointly by Hanshow, Intel, and Microsoft. It summarizes changes in the global retail industry and best practices in the retail + AI sector. By examining Hanshow’s partners in China, Japan, and Europe, the whitepaper also illustrates how smart retail technology in the AI era works for global retailers and describes the future development and application trend of AI technology in the retail industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907005647/en/
Smart store powered by Hanshow (Photo: Business Wire)
AI Technology Innovation Improves Business & Customer Experience
Digitalization is reshaping the global retail industry. Innovative technologies, including AI, computer vision, and the Internet of Things (IoT), are therefore becoming the core tools helping retailers reduce operating costs, improve efficiency, and bring unique shopping experiences to customers. More retailers are using AI technology as a key element to improve business, increase revenue, gain insights into consumer preferences, and optimize store operations.
Liangyan Li SVP, Head of Global Sales, Hanshow, said “Hanshow shall cooperate with leading international companies such as Intel and Microsoft to continuously explore the evolution of AI + retail, unlock the value of data, provide more retailers with better products and solutions, and contribute to the transformation of the global retail market.”
Hanshow Joins Intel and Microsoft to Launch AI Retail Program
Together with Intel and Microsoft, Hanshow therefore has launched AI solutions for the retail industry, focusing on smart shelf management and self-service cashier loss prevention. The use of technology, such as AI cameras and robots, enables retailers to determine the amount of displayed and out-of-stock products with an accuracy of over 95%, by collecting data through commodity identification, and stock inspection. Meanwhile, the edge devices in the scheme solve the problem of sensitive data protection, as well as collect and transmit relevant data for further processing to help businesses find trends and make decisions.
Long-Term Transformative Benefits of AI Solutions for the Retail Industry
The partnership among Hanshow, Intel, and Microsoft in the retail sector has successfully driven the application of AI in the industry. Especially in the post-pandemic period, the digital transformation of the retail industry will help retailers to provide users with a unique and personalized offline service experience to regain their interest and achieve higher business growth.
Guo Wei, General Manager of NEX and Channel DCAI Sales team, PRC Sales Organization, Intel, said " With digital technologies such as AI, virtualization, IoT, and edge computing realizing the upgrade of personalized consumer experiences and the reshaping of innovation-driven retail, the industry is experiencing a lot of changes. ”
Rashmi Misra, General Manager, Microsoft AI & Emerging Technologies, said "AI and IoT are transforming business models by helping companies move from simply making products and services, to companies that give their customers desired outcomes and impeccable experience."
Raj Raguneethan, Regional Business Lead, Retail & Consumer Goods, Microsoft Asia, said “Through the extensive application of AI, retail can become smart, providing better operational excellence, intelligent supply chain, and stronger business intelligence."
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow is used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom